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AbstrACt
Objective To develop a predictive model for fetal loss in 
women with systemic lupus erythematosus (SLE).
Design A retrospective cohort study.
setting Data were collected in a tertiary medical centre, 
located in Shanghai, China, from September 2011 to May 
2017.
Participants 338 pregnancies with SLE were analysed 
retrospectively. Cases of multiple pregnancy and those 
in which artificial abortion was performed for personal 
reasons were excluded.
Primary outcome measures Fetal loss was the primary 
outcome. A stepwise regression to identify the predictors 
related to the fetal loss and coefficient B of each variable 
was used to develop a predictive model and make a 
corresponding risk classification. The Hosmer-Lemeshow 
test, Omnibus test and area under the receiver-operating 
characteristic curve (AUC) were used to assess the 
goodness-of-fit and discrimination of the predictive model. 
A 10-fold cross validation was used to assess the model 
for overfitting.
results Unplanned pregnancies (OR 2.84, 95% CI 
1.12 to 7.22), C
3 hypocomplementemia (OR 5.46, 
95% CI 2.30 to 12.97) and 24 hour-urinary protein level 
(0.3≤protein<1.0 g/24 hours: OR 2.10, 95% CI 0.63 to 
6.95; protein≥1.0 g/24 hours: OR 5.89, 95% CI 2.30 to 
15.06) were selected by the stepwise regression. The 
Hosmer-Lemeshow test resulted in p=0.325; the Omnibus 
test resulted in p<0.001 and the AUC was 0.829 (95% CI 
0.744 to 0.91) in the regression model. The corresponding 
risk score classification was divided into low risk (0–3) 
and high risk groups (>3), with a sensitivity of 60.5%, a 
specificity of 93.3%, positive likelihood ratio of 9.03 and 
negative likelihood ratio of 0.42.
Conclusions A predictive model for fetal loss in women 
with SLE was developed using the timing of conception, 
C
3 complement and 24 hour-urinary protein level. This 
model may help clinicians in identifying women with high 
risk pregnancies, thereby carrying out monitoring or/and 
interventions for improving fetal outcomes.
IntrODuCtIOn   
Systemic lupus erythematosus (SLE) is a 
multisystem autoimmune disease, and it 
primarily affects women of childbearing 
age. Women with SLE have normal fertility 
rate,1 and pregnancy is therefore a frequent 
subject of interest to these patients. Adverse 
pregnancy outcomes are common in this 
population, with an estimated 20% ending in 
miscarriage and 3% in stillbirth.2 As the treat-
ment of SLE has greatly improved over the 
past two decades, the majority of SLE women 
can carry out a live birth delivery.3 Predic-
tion of pregnancy outcomes for patients 
with SLE can significantly contribute towards 
providing effective preconception consulta-
tion and treatment as well as prevent adverse 
pregnancy outcome and complications. 
Advice about safety and timing of concep-
tion requires identification of clinical and 
laboratory variables that predict fetal loss and 
other adverse pregnancy outcomes.4 While 
numerous studies have identified risk factors 
for fetal loss in pregnant women with SLE, 
such as lupus nephritis,5–7 SLE activity during 
6 months before pregnancy,8 low comple-
ment levels,9 antiphospholipid syndrome, 
anti-SSA/Ro antibodies, thrombocytopenia10 
strengths and limitations of this study
 ► This study developed a prediction model and risk 
score classification for systemic lupus erythemato-
sus fetal loss.
 ► The model of prediction has a good fit and discrimi-
nation, as does the risk score classification, indicat-
ing a higher predictive value.
 ► The risk score classification is clinically practical, 
as the model is simple and the variables included 
are routinely collected during the first antenatal care 
visit.
 ► The limitation of this model was the development 
and validation process applied the same cohort. 
Although 10-fold cross-validation was performed 
and had a good result, it still cannot assess the gen-
eralisability of this model.
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and many other factors have been introduced in previous 
studies,11–17 results varied among studies. The numerous 
risk factors and the complicated relationships among 
these factors necessitate the development of a clinical 
prediction model. It is essential and helpful if the clini-
cian is able to predict the risk of fetal loss in pregnant 
patients with SLE in the early stages of gestation, which 
can allow special monitoring and treatment as early as 
possible. Application of prediction model in pregnancy 
has been studied for years15 18; However, very few studies4 19 
have proposed such a predictive model or risk score in 
predicting the fetal loss risk in SLE women. We therefore 
conducted a retrospective study at a tertiary hospital in 
Shanghai, China and sought to identify clinical and labo-
ratory predictors for fetal loss in pregnant patients with 
SLE to develop a risk score and classification.
MAterIAls AnD MethODs
study design and population
This was a retrospective, observational study performed 
at Ren Ji Hospital, Shanghai Jiao Tong University School 
of Medicine, Shanghai, China. Our study population 
included all the pregnant women treated for SLE between 
September 2011 and May 2017. Patients with multiple 
gestations and those who underwent artificial abortions 
due to personal reasons were excluded from this analysis. 
A total of 338 pregnancies with SLE were included in the 
final analysis. SLE was diagnosed according to the revised 
criteria for classification of SLE developed by the Amer-
ican College of Rheumatology.20
Variables of interest
Baseline characteristics of interest included maternal age 
at delivery, region, parity, the history of spontaneous or 
therapeutic abortions. Regions were categorised as either 
urban or rural areas. Clinical information included SLE 
clinical features and laboratory information from the 
first antenatal care records (16–20 weeks). Comorbid-
ities included a pre-pregnancy diagnosis of hyperten-
sion or diabetes. No women in the study population 
were smokers or drinkers, so lifestyle (eg, smoking and 
drinking) was not analysed in this study. With respect to 
different timings of conception, patients were divided 
into a planned pregnancy group, which consisted of 
patients who had controlled SLE or were in remission 
for more than 6 months prior to conception and an 
unplanned pregnancy group, which consisted of patients 
with active lupus disease before conception or new onset 
SLE during pregnancy. SLE Disease Activity Index 2000 
(SLEDAI-2K) was used as a valid measure of disease 
activity and SLEDAI-2K>4 was defined as an active stage of 
SLE.21 Laboratory data included a complete blood count, 
urinalysis, serum albumin, 24 hours urinary protein, 
complement 3 (C3), complement 4 (C4), antinuclear anti-
bodies, anti-dsDNA antibodies (anti-dsDNA), anti-Smith 
antibodies(anti-Sm), anti-SSA/Ro antibodies, anti-SSB/
La antibodies and antiphospholipid (aPL) antibodies, 
which included anticardiolipin antibodies (aCL), 
anti-2-glycoprotein I antibodies (anti-β2GPI) and lupus 
anticoagulant (LA). All laboratory tests were performed 
using standardised methods.
The gestational age of fetal loss or delivery and birth 
weight were also recorded. Abstracted fetal outcomes and 
definitions were as follows:
 ► Live birth: the birth of a living child.
 ► Preterm birth: delivery prior to 37 weeks of gestation.
 ► Low birth weight (LBW): birth weight ≤2500 g, regard-
less of gestational age and circumstances.22 LBW 
infants were divided into term LBW and preterm 
LBW based on their gestational age.
 ► Fetal loss: included spontaneous abortions, ther-
apeutic abortions, stillbirths or intrauterine fetal 
deaths and neonatal deaths. Additional definitions 
were as follows:
 – Spontaneous abortion: spontaneous termination 
of pregnancy prior to 28 weeks of gestation.
 – Therapeutic abortion: abortion for therapeutic 
reasons because the pregnancy might be a threat 
to maternal health, such as life-threatening SLE 
flare23 or other severe obstetric complications, 
including severe thrombocytopaenia or HELLP 
(haemolysis, elevated liver enzymes, and low plate-
let count) syndrome and so on.
 – Stillbirth or intrauterine fetal death: any baby born 
without signs of life at greater than or equal to 28 
completed weeks of gestation.24
 – Neonatal death: death of a live-born baby within 
the first 28 days of life.25
Patient and public involvement
Patients and the public were not involved in the design 
and conception of the study and there are no plans to 
disseminate the results to patients.
statistical analysis
Descriptive data are shown as the mean±SD or as a 
frequency. Categorical variables were analysed using χ² or 
Fisher’s exact probability tests as appropriate. Continuous 
variables were analysed using Student’s t test where the 
distribution are normal.
Multivariable analysis was performed by selecting vari-
ables with p<0.05 in the univariate analysis as potential 
predictors as well as changing included continuous vari-
ables into categorical variables. Logistic regression was 
applied to assess the OR and 95% CIs of fetal loss for all 
potential predictors separately and together, adjusting 
for confounding factors. Then stepwise regression was 
used (p<0.05 for the forward and p<0.10 for the back-
ward steps), adjusting for confounding factors, to iden-
tify those factors that were most predictive of fetal loss in 
pregnant patients with SLE.26
Variables that were significant in the stepwise regres-
sion analysis were used to measure the risk of fetal loss in 
patients with SLE using the equation:
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  P =
eY
1+eY   (1)
Y was estimated from the coefficients of variables in the 
logistic regression analysis. Goodness-of-fit test for the 
regression model was assessed using the Hosmer-Leme-
show test and Omnibus test, and the area under the receiv-
er-operating characteristics (ROC) curve (AUC) was used 
to assess the discrimination of the regression model. To 
assess model overfitting, we used a 10-fold cross valida-
tion.19 26 27
A risk scoring system was constructed to classify the fetal 
loss risk of pregnant patients with SLE. This risk score was 
calculated using the regression coefficient B of each vari-
able in the logistic regression model, using the equation:
  
∣∣∣∣ BVBmin
∣∣∣∣ = Score
  (2)
BV=regression coefficient B of each variable.
A cumulative risk score was calculated for every 
patient.28 ROC curves were plotted, with 1–specificity 
and sensitivity measured along the horizontal and vertical 
axes, respectively, with all possible cumulative risk scores 
in all patients used as cut-off points in the prediction 
of fetal loss in pregnant patients with SLE. Sensitivity, 
specificity, accuracy, positive predictive value, negative 
predictive value, positive likelihood ratio and negative 
likelihood ratio were used to find the best cut-off of the 
scoring system.
All tests were two-tailed, and p<0.05 was considered 
statistically significant. All analyses were performed using 
SPSS V.22.0 and R Studio V.3.4.1.
ethics statement
The research protocol used in this study was reviewed and 
approved by the Ethics Committee of Ren Ji Hospital, 
Shanghai Jiao Tong University School of Medicine (2017–
113). As this was a retrospective observational study, the 
Medical Ethical Committee granted a waiver for informed 
consent for this study. Approval to obtain clinical data 
from the database was received from the office of the 
medical director of the hospital. All patient information 
was kept confidential.
results
Population characteristics
A total of 338 pregnancies with SLE were included in 
this analysis. Their baseline characteristics are shown in 
table 1. The mean age at conception was 29.5±4.0 years 
(range, 20–40 years), and the mean time between SLE 
diagnosis and pregnancy was 5.7±4.3 years (range, 0–20 
years). The frequency of therapeutic abortions ranged 
from 0 to 2 times, and the frequency of spontaneous 
abortions ranged from 0 to 7 times. Almost 70% of the 
pregnancies with SLE were from urban areas. Of the 
patients, 291 (86.1%) were nulliparous. With respect to 
comorbid conditions, only 1 patient had pre-pregnancy 
diabetes (not shown in the table) and 10 patients had 
pre-pregnancy hypertension. There were 293 (86.7%) 
planned and 45 (13.3%) unplanned pregnancies. The 
most common SLE clinical manifestations were muco-
cutaneous lesions, which were identified in 31.4% of 
patients. The mean 24 hour-urinary protein level was 
1.04±2.43 g (range, 0.01–16.69 g). Forty-six patients were 
positive for aPL antibodies. C3 and C4 hypocomplemen-
temia was present in 90 (26.6%) and 60 patients (17.8%), 
respectively.
Fetal outcomes
A total of 300 live births (88.8%) and 38 fetal losses 
(11.2%) was recorded. Eighty-six pregnancies (25.4%) 
were preterm births, and 68 neonates had LBWs 
(including 13 full-term births). Among the pregnancies 
that ended with a fetal loss, 11 (28.9%) were spontaneous 
abortions, 21 (55.3%) were therapeutic abortions and 6 
(15.8%) were stillbirths. There were four live births with 
congenital malformations, of which one had small atrial 
septal defect, two had renal problems and one had poly-
dactyly. There were no neonatal deaths (online supple-
mentary table S1).
risk factors of fetal loss among sle pregnancies
As shown in table 2, unplanned pregnancies, pre-preg-
nancy hypertension, C3 and C4 hypocomplementemia, 
renal disorders, haematological disorders, the presence 
of anti-dsDNA and elevated 24 hour-urinary protein 
levels were significantly associated with fetal loss in the 
univariate analysis. To make it easier to apply clinically, 
the 24 hour-urinary protein variable was classified into 
a categorical variable based on the available clinical 
reference.29
The association between each potential predictor 
and the risk of fetal loss was statistically significant. A 
24 hour-urinary protein level ≥1.0 g/24 hours had the 
highest OR at 14.85 (95% CI 6.25 to 35.31), followed by C3 
hypocomplementemia (OR 11.43, 95% CI 5.15 to 25.33). 
When all potential predictors were included in the model, 
only 24 hour-urinary protein ≥1.0 g/24 hours and C3 
hypocomplementemia remained statistically significant. 
This was likely because of the relatively high correlation 
between potential predictors. A Spearman correlation 
was performed, and the result is shown in online supple-
mentary table S2. Using a stepwise regression, unplanned 
pregnancy status (OR 2.84, 95% CI 1.12 to 7.22), C3 hypo-
complementemia (OR 5.46, 95% CI 2.30 to 12.97) and 24 
hour-urinary protein level (0.3≤protein<1.0 g/24 hours: 
OR 2.10, 95% CI 0.63 to 6.95; protein≥1.0 g/24 hours: 
OR 5.89, 95% CI 2.30 to 15.06) were selected for further 
analysis.
the prediction model and risk score for fetal loss among 
pregnancies with sle
Table 3 shows the B regression coefficient estimate in the 
multivariable analysis model. Using the method described 
above, the result of the Hosmer-Lemeshow test was 
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p=0.325 (χ2=4.652, df=4) and Omnibus test was p<0.001 
(χ2=66.255, df=4), which indicated that the logistic regres-
sion model had a good fit. The AUC was 0.829 (95% CI 
0.744 to 0.914, SE=0.043, p<0.01), which indicated that 
the model has good discrimination (figure 1). The 10-fold 
cross-validation for this model was 90.0% accurate.
The fetal loss risk score was calculated using the 
following equation:
Fetal loss risk score= ‘Unplanned pregnancy’ SCORE 
+‘hypocomplementemia-C3’ SCORE + ‘24 hour-Urinary 
protein’ SCORE
Figure 2 shows the cumulative risk score and the asso-
ciated risk of fetal loss in pregnant patients with SLE. As 
shown in the figure, the fetal loss rate generally increased 
when the risk score rose.
ROC curve coordinates and potential cut-offs for the 
risk score system were estimated using a detailed process 
shown in online supplementary tables S3–S6.
A score of 3 was the best cut-off point (sensitivity=60.5%, 
specificity=93.3%, accuracy=89.6%, positive predictive 
value=53.5%, negative predictive value=94.9%, positive 
likelihood ratio=9.03, and negative likelihood ratio=0.42). 
The risk classification for fetal loss according to the risk 
score system is shown on table 4.
For example, a pregnant woman with SLE who went to 
antenatal care at 18 weeks was diagnosed with new-onset 
SLE during pregnancy (1), had a lower C3 comple-
ment level (2) and had a 24 hour-urinary protein of 
0.8 g/24 hours (1) would have a cumulative risk score of 
4, which belongs in the high risk for fetal loss group.
Table 1 Patients’ characteristics during pregnancy
Variables
Total
n=338(%)
Live birth
n=300 (%)
Fetal loss
n=38 (%) P value
Characteristics
  Age (year, mean±SD) 29.5±4.0 29.7±3.9 28.6±4.5 0.131
  History of SLE (year, mean±SD) 5.7±4.3 5.8±4.4 4.5±4.1 0.091
  History of therapeutic abortion
  (frequency, mean±SD, range)
0.04±0.2
(0–2)
0.04±0.2
(0–1)
0.08±0.4
(0–2)
0.657
  History of spontaneous abortion (frequency, mean±SD, 
range)
0.4±0.9
(0–7)
0.4±1.0
(0–7)
0.3±0.6
(0–7)
0.687
  Region
   City 237 (70.1) 210 (70.0) 27 (71.1) 0.894
   Rural 101 (29.9) 90 (30.0) 11 (28.9)
  Nullipara 291 (86.1) 258 (86.0) 33 (86.8) 0.888
  Pre-pregnancy hypertension 10 (3.0) 6 (2.0) 4 (10.5) 0.016*
  Unplanned pregnancy 45 (13.3) 32 (10.7) 13 (34.2) <0.001*
SLE clinical features
  Renal disorder 97 (28.7) 76 (25.3) 21 (55.3) <0.001*
  Mucocutaneous 106 (31.4) 94 (31.3) 12 (31.6) 0.975
  Haematological disorder 66 (19.5) 53 (17.7) 13 (34.2) 0.015*
  Neurological disorder 5 (1.5) 3 (1.0) 2 (5.3) 0.181
  Arthritis 70 (20.7) 63 (21.0) 7 (18.4) 0.712
  Serositis 17 (5.0) 10 (3.3) 7 (18.4) 0.001*
Laboratory features during pregnancy
  24 hour-urinary protein (g, mean±SD) 1.04±2.43 0.6±1.5 4.3±4.9 <0.001*
  Anti-dsDNA 261 (77.2) 226 (75.3) 35 (92.1) 0.020*
  Anti-Ro/SSA 150 (44.4) 132 (44.0) 18 (47.4) 0.694
  Anti-La/SSB 47 (13.9) 41 (13.7) 6 (15.8) 0.722
  Anti-Sm 20 (5.9) 16 (5.3) 4 (10.5) 0.361
  aPL 46 (13.6) 38 (12.7) 8 (21.1) 0.156
  hypocomplementemia-C3 90 (26.6) 62 (20.7) 28 (73.7) <0.001*
  hypocomplementemia-C4 60 (17.8) 45 (15.0) 15 (39.5) <0.001*
*P<0.05.
SLE, systemic lupus erythematosus.
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DIsCussIOn
Principal findings of the study
In this study, we showed that pregnant women with SLE 
have a high risk of adverse fetal outcomes, including fetal 
loss, preterm births and LBWs. Unplanned pregnancies, 
hypocomplementemia C3 and an elevated 24 hour-uri-
nary protein level were independent risk factors for fetal 
loss after adjusting for possible confounders. Patients can 
be classified into different risk groups based on the values 
of these three variables, which may help obstetricians and 
rheumatologists predict pregnancy outcomes.
Comparison with previous studies
Significant progress has been made in the study and ante-
natal care monitoring of pregnancies complicated with 
SLE. In recent decades, most women with SLE can have 
a more favourable pregnancy outcome.6 8 However, fetal 
loss and other adverse fetal outcomes remain common in 
the SLE population.30–32
Fetal loss rates have ranged from 3% to 43% in prior 
studies.8 10 11 13 14 31 33 Our total fetal loss rate was 11.2%, 
which falls at the lower end of what was reported in the 
literature. Two other recent Chinese studies reported 
Figure 1 ROC curve of the prediction model. ROC, receiver-
operating characteristic. 
Table 2 Multivariable analysis of fetal loss
Variables
Risk factors included 
individually
Risk factors included 
simultaneously
Risk F actors selected 
using stepwise 
regression
OR (95% CI) OR (95% CI) OR (95% CI)
Unplanned pregnancy 4.33 (1.71 to 11.00)** 3.01 (0.90 to 10.02) 2.84 (1.12 to 7.22)*
Pre-pregnancy hypertension 6.45 (1.60 to 26.06)** 5.24 (0.74 to 37.38) –
hypocomplementemia-C3 11.43 (5.15 to 25.33)** 7.09 (2.60 to 19.36)** 5.46 (2.30 to 12.97)**
hypocomplementemia-C4 3.80 (1.81 to 7.98)** 0.56 (0.19 to 1.60) – 
Renal disorder 3.58 (1.76 to 7.28)** 0.33 (0.09 to 1.15) – 
Haematological disorder 2.19 (1.02 to 4.69)* 0.90 (0.32 to 2.53) – 
Anti-dsDNA 3.62 (1.07 to 12.17)* 2.58 (0.65 to 10.24) –
24 hour-urinary protein
  Urinary protein<0.3 g/24 hours 1 1 1
  0.3≤urinary protein<1.0 g/24 hours 3.34 (1.05 to 10.68)* 3.23 (0.90 to 11.65) 2.10 (0.63 to 6.95)
  Urinary protein≥1.0 g/24 hours 14.85 (6.25 to 35.31)** 16.20 (3.90 to 67.29)** 5.89 (2.30 to 15.06)**
*P<0.05; **P<0.01; Multivariable models adjusted for age at conception (continuous), history of SLE (continuous), history of therapeutic 
abortion (continuous), history of spontaneous abortion (continuous), region (city vs rural), nullipara (nullipara vs multipara).
SLE,  systemic lupus erythematosus . 
Table 3 Adjusted OR and B coefficient from cohort with 
multivariable logistic regression model and corresponding 
risk score
Variables
Adjusted 
OR B Score
Unplanned pregnancy
  Planned pregnancy 1 0
  Unplanned pregnancy 2.84 1.04 1
hypocomplementemia-C3
  Non-hypocomplementemia-C3 1 0
  hypocomplementemia-C3 5.46 1.70 2
24 hour-urinary protein
  Urinary protein<0.3 g/24 hours 1 0
  0.3≤Urinary 
protein<1.0 g/24 hours
2.10 0.74 1
  Urinary protein≥1.0 g/24 hours 5.89 1.77 2
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a relatively low rate of fetal loss.10 13 Whether Chinese 
patients with SLE have a lower fetal loss rate than those 
from other ethnicities requires further study.
Our data showed that in the univariate analysis, 
unplanned pregnancies, hypocomplementemia C3and 
24 hour-urinary protein levels improved our outcome 
predictions better than other variables and were selected 
by stepwise regression models. These three variables were 
stronger predictors of the overall risk of fetal loss. Clowse 
et al reported that regardless of SLE activity, low comple-
ment levels during the second trimester were associated 
with a higher rate of pregnancy loss and preterm births.9 
Few studies observed an association between fetal loss and 
24 hour-urinary protein level, which is a very easy and prac-
tical laboratory test to perform. Our study first compared 
24 hour-urinary protein level as a continuous variable 
and found it to be significantly higher in fetal loss group. 
When performing the multivariable analysis and devel-
oping our risk score, we converted 24 hour-urinary protein 
level into a categorical variable based on clinical practice, 
which was as follows: urinary protein <0.3 g/24 hours; 
0.3≤urinary protein <1.0 g/24 hours; urinary 
protein ≥1.0 g/24 hours.29 The presence of urinary 
protein ≥1.0 g/24 hours was a strong predictor of fetal 
loss, even in our multivariable analysis. Other studies 
reported that the presence of active lupus nephritis 
increased the risk of fetal loss.5 6 11 34 However, few studies 
failed to observe an association between lupus nephritis 
and fetal loss.10 14 35 A Chinese retrospective study of 111 
pregnant patients with SLE found that proteinuria was a 
predictor for fetal loss in a univariate analysis, but was not 
associated with fetal loss in a multivariable analysis,13 a 
finding that may be due to the small sample size.
SLE activity during pregnancy is a well-known risk factor 
for a poor fetal outcome. Teh et al found that SLE flares 
contributed to 60.0% of fetal losses in Malaysia.12 Zhan et 
al also reported that patients with active lupus had a 12.4-
fold higher risk of fetal loss in a retrospective study of 263 
pregnant patients with SLE.8 Ku et al found that patients 
with new-onset SLE during pregnancy had a significantly 
higher rate of fetal loss (73.7% vs 15.6%, p<0.01).14 Lateef 
et al suggested that optimal disease control for at least 6 
months prior to conception should be ensured to reduce 
the risk of fetal loss.36 In our study, we divided patients 
into planned and unplanned pregnancy groups based 
Figure 2 Fetal loss risk in pregnant patients with SLE based on their cumulative risk score. SLE, systemic lupus 
erythematosus. 
Table 4 The risk classification for fetal loss according to 
the risk score system
Risk N %
Fetal 
loss (N)
Fetal 
loss (%)
Low risk (0–3) 295 87.3 15 5.1
High risk (>3) 43 12.7 23 53.5
Total 338 100 38 11.2
P<0.01.
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on conception timing, which we believe to be easier and 
more practical for clinicians to use. Our results were 
consistent with those of previous studies.
Several studies focused on the risk factors for fetal 
loss in pregnant patients with SLE in different settings. 
For example, Al Arfaj et al found that lupus nephritis 
(OR=7.3), aPL antibodies (OR=3.9), and SLE flares 
during pregnancy (OR=1.9) were predictors of fetal loss.11 
Clowse et al reported that live birth rates were strongly 
affected by high lupus activity.37 In 2016, Tian et al studied 
2026 Chinese pregnant women with SLE and found that 
aPL, anti-SSA antibodies and thrombocytopaenia were 
associated with fetal loss, and arthritis was associated with 
a favourable fetal outcome.10 However, very few studies 
attempted to establish a risk score classification. Here, we 
developed a prediction model with a risk score classifi-
cation that is simple to use and has predictors that are 
very easy to obtain clinically. Paydar et al developed a clin-
ical decision support system to help physicians predict 
pregnancy outcomes in women with SLE. It was well-de-
veloped and had a high predictive accuracy. However, it 
included 16 variables and required specific software that 
was not easy for clinicians to obtain.19
strengths and limitations
The present study is noteworthy for several reasons. While 
other studies have reported on the risk factors for fetal 
loss in pregnant patients with SLE, to our knowledge, no 
other study has developed a prediction model and risk 
score classification for SLE fetal loss, which is one of the 
most important fetal outcomes in pregnancies of mothers 
with SLE. Additionally, the present study included a rela-
tively large sample size. Further, our prediction model 
has a good fit and discrimination, as does the risk score 
classification, indicating a higher predictive value. Finally, 
the risk score classification is clinically practical, as the 
model is simple and the included variables are routinely 
collected during the first antenatal care visit.27
Nevertheless, our study has some limitations. First, as 
there are limited pregnancies in patients with SLE, the 
development and validation process of this model has to 
apply to the same cohort. Although 10-fold cross-valida-
tion was performed and had a good result, it still cannot 
assess the generalisability of this model. It would be better 
to have an external validation in the future.38 Second, as 
a retrospective study, this study has inherent information 
bias. Finally, clinical records lacked additional details 
regarding baseline population characteristics, such as 
education level, body mass index, family income and so 
on. These factors may be confounders in this study.
Future direction
In future, a prospective study will be conducted and 
more patients will be recruited for further analysis to vali-
date this predictive model. Moreover, since pregnancy 
is a 10-month process, the relationship between preg-
nancy outcome and the trend of laboratory parameters 
rather than a single time point result need to be further 
explored. Finally, the effects and safety of different kinds 
of medicine will be further observed and elucidated in 
pregnant women with SLE.
COnClusIOn
The predictive model proposed in this study permits a 
quick and high quality estimate of the risk of fetal loss 
among pregnancies with SLE at their first antenatal care 
visit (16 W-20 W), which is an essential step in SLE ante-
natal care. Identifying a high-risk group, strengthening 
monitoring or/and intervening at an early gestational 
stage may potentially improve fetal outcomes.
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